Special Issue "Marine Drugs as Antitumour Agents"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 August 2010)
Prof. Dr. Mark Searcey
School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK
Phone: +44 01603 592026
Fax: +44 01603 592003
Interests: natural products in medicinal chemistry; higher order nucleic acid structures; new targets for cancer research and protein-protein interactions
The recent introduction to the clinic of trabectedin (Et-743) as a treatment for soft tissue sarcoma highlights the potential of marine drugs as novel antitumour agents. There is a huge and largely untapped array of small molecules in the depths of the ocean, produced by novel organisms that are only now being discovered. Other compounds that have captured the imagination include the dolastatins, bryostatins, kahalalides, didemnins, halchondrins, lamellarins and thiocaroline. The structurally diversity among this compounds is immense, from cyclic and linear peptides to products of the polyketide and alkaloid biosyntehsis pathways. There are diterpenes, pyrrole alkaloids, depsipeptides, macrolides and steroids. The targets for these natural products show a similar array of diversity, from tubulin inhibitors to other protein targets such as caspases and cyclin dependent kinases. The isolation and identification of new marine natural products with antitumour activity with be a key feature of this special issue of Marine Drugs. However, as with all natural products, these compounds were not produced in nature to act as antitumour agents, and while it may seem arrogant to suggest that we can improve on nature, this is where total synthesis and studies of structure activity relationships come into their own. The total synthesis of new natural products is clearly still of great important in the elucidation and confirmation of structure and absolute stereochemistry. But it also can contribute to our understanding of the mechanism of action of the natural product as an antitumour agent and can contribute to the design of analogues with enhanced activity. The second focus of this special issue of Marine Drugs will be on the synthesis and study of the mode of action of antitumour agents derived from the Sea.
Dr. Mark Searcey
- antitumour agents
- marine compounds
- total synthesis
- structure-activity relationships
- medicinal chemistry
- biological activity
Mar. Drugs 2010, 8(10), 2702-2720; doi:10.3390/md8102702
Received: 31 August 2010; in revised form: 17 September 2010 / Accepted: 13 October 2010 / Published: 15 October 2010| Download PDF Full-text (493 KB) | View HTML Full-text | Download XML Full-text
Article: Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes
Mar. Drugs 2010, 8(10), 2659-2672; doi:10.3390/md8102659
Received: 31 August 2010; in revised form: 6 October 2010 / Accepted: 12 October 2010 / Published: 14 October 2010| Download PDF Full-text (307 KB) | View HTML Full-text | Download XML Full-text | Supplementary Files
Mar. Drugs 2010, 8(7), 2129-2141; doi:10.3390/md8072129
Received: 8 May 2010; in revised form: 11 June 2010 / Accepted: 8 July 2010 / Published: 13 July 2010| Download PDF Full-text (297 KB) | View HTML Full-text | Download XML Full-text
Last update: 27 February 2014